Office of Infectious Diseases (OID)
The Office of Infectious Diseases (OID) within the Office of New Drugs oversees the review and regulation of applications for drugs to prevent or treat infectious diseases. OID consists of three review divisions:
- Division of Anti-Infectives (DAI) regulates drug products to prevent or treat infectious diseases caused by bacteria, fungi, or parasites.
- Division of Antivirals (DAV) regulates drug products for prevention or treatment of infections caused by viruses.
- Division of Pharmacology/Toxicology for Infectious Diseases (DPT-ID) provides review and consultation of issues related to nonclinical toxicology and safety risk assessment for all products regulated by DAI and DAV.
Resources:
- FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria
- FDA Response to Antimicrobial Resistance
- Tropical Disease Priority Review Voucher Program
- OID Research Activities
- Guidances: For DAI, DAV and DPTID specific and/or relevant guidance documents (draft or final)
- Advisory Committee Meetings: Antimicrobial Drugs Advisory Committee (formerly known as the Anti-Infective Drugs Advisory Committee)
- Public Meetings (Upcoming and Past)
Contact Us
Mailing Address:
Food and Drug Administration
Center for Drug Evaluation and Research
Central Document Room
Attention: Office of Infectious Diseases
5901-B Ammendale Road
Beltsville, MD 20705-1266
Phone: (301) 796-1300